StockData
Virax Biolabs Group Ltd logo

Virax Biolabs Group Ltd (VRAX) stock

VRAXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends March 31
Financials through fiscal 2026, year ended Mar 31, 2026Last filing: 20-F on Jul 6, 2026Score 9/30
$0.43−0.02 (-3.39%)

Close on Nov 18, 2026Market cap $249.06KP/E –Yield –

Virax Biolabs operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

For fiscal 2026 it was -$6.40M. The highest annual figure on record is -$644.54K in fiscal 2021.

Annual operating income

PeriodPeriod endValueChange
FY2026Mar 31, 2026-$6.40M–
FY2025Mar 31, 2025-$6.08M–
FY2024Mar 31, 2024-$6.53M–
FY2023Mar 31, 2023-$5.73M–
FY2022Mar 31, 2022-$1.73M–
FY2021Mar 31, 2021-$644.54K–

More Virax Biolabs figures

See a number that looks wrong?